

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Shuji Ozaki et al.	Art Unit	: 1614
Serial No.	: 10/530,696	Examiner	: Unknown
Filed	: April 8, 2005		
Title	: CELL DEATH-INDUCING AGENT		

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Translations of references AD, AE, and AF are not included, since they are members of the patent family of English language references AG, AH, and AI, respectively. Also enclosed are copies of an International Search Report, an International Preliminary Examination Report, and a Supplementary European Search Report received for counterpart applications.

Applicants wish to bring to the Examiner's attention co-pending and co-owned non-provisional application serial numbers 10/548,727 (Attorney Docket No. 14875-150US1), 10/550,934 (Attorney Docket No. 14875-151US1), 10/551,504 (Attorney Docket No. 14875-153US1), 10/582,176 (Attorney Docket No. 14875-163US1), 10/582,413 (Attorney Docket No. 14875-164US1), and 10/582,304 (Attorney Docket No. 14875-166US1), all of which have overlapping inventorship with the above-referenced application and concern related subject matter. Applicants assume that the Examiner has ongoing access to the files of these related applications and can obtain copies of prosecution documents from the files if at any point in the future he/she considers it potentially relevant to issues in the present application. Applicants will supply copies of such documents from the related applications' files, should the Examiner request them.

Applicant : Shuji Ozaki et al.  
Serial No. : 10/530,696  
Filed : April 8, 2005  
Page : 2 of 2


Attorney's Docket No.: 14875-141US1 / C1-A0220P-US

This statement is being filed before the receipt of a first Office Action on the merits.  
Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

June 30, 2006

A handwritten signature in dark ink, appearing to read "Janis K. Fraser", written over a horizontal line.

Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-141US1</b>	Application No. <b>10/530,696</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Shuji Ozaki et al.</b>	
		Filing Date <b>April 8, 2005</b>	Group Art Unit <b>1614</b>

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,183,744	02/06/2001	Goldenberg			
	AB	6,368,596	04/09/2002	Ghetie et al.			
	AC	2003/0148409	08/07/2003	Rossi et al.			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD	JP 10-505231	05/26/1998	Japan			see AG	
	AE	JP 2001-518930	10/16/2001	Japan			see AH	
	AF	JP 2002-544173	12/24/2002	Japan			see AI	
	AG	WO 96/04925	02/22/1996	WIPO				
	AH	WO 98/42378	10/01/1998	WIPO				
	AI	WO 00/67795	11/16/2000	WIPO				
	AJ	WO 01/74388	10/11/2001	WIPO				
	AK	WO 01/97858	12/27/2001	WIPO				
	AL	WO 02/04021	01/17/2002	WIPO				
	AM	WO 02/22212	03/21/2002	WIPO				
	AN	WO 03/033654	04/24/2003	WIPO				
	AO	WO 03/104425	12/18/2003	WIPO				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AP	Daniel et al., "Induction of Apoptosis in Human Lymphocytes by Human Anti-HLA Class I Antibodies," <i>Transplantation</i> , 75:1380-1386 (2003)
	AQ	Fayen et al., "Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events," <i>Int. Immunol.</i> , 10:1347-1358 (1998)
	AR	Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnol. Adv.</i> , 18:385-401 (2000)
	AS	Genestier et al., "Antibodies to HLA Class 1 $\alpha$ 1 Domain Trigger Apoptosis of CD40-Activated Human B Lymphocytes," <i>Blood</i> , 90:726-735 (1997)
	AT	Genestier et al., "Caspase-dependent Ceramide Production in Fas- and HLA Class I-mediated Peripheral T Cell Apoptosis," <i>J. Biol. Chem.</i> , 273:5060-5066 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-141US1</b>	Application No. <b>10/530,696</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Shuji Ozaki et al.</b>	
		Filing Date <b>April 8, 2005</b>	Group Art Unit <b>1614</b>

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AU	Genestier et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I $\alpha$ 1 Domain," <i>Blood</i> , 90:3629-3639 (1997)
	AV	Genestier et al., "T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2 and interleukin-4," <i>Eur. J. Immunol.</i> , 27:495-499 (1997)
	AW	Goto et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells," <i>Blood</i> , 84:1922-1930 (1994)
	AX	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. USA</i> , 90:6444-6448 (1993)
	AY	Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-C <sub>H</sub> 3) Which Exhibits Rapid, High-Level Targeting of Xenografts," <i>Cancer Res.</i> , 56:3055-3061 (1996)
	AZ	Kimura et al., "2D7 diabody bound to the $\alpha$ 2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells," <i>Biochem. Biophys. Res. Commun.</i> , 325:1201-1209 (2004)
	AAA	Kreitman et al., "Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias," <i>Clin. Cancer Res.</i> , 6:1476-1487 (2000)
	ABB	Kulkarni et al., "Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility Complex," <i>Transplant. Proc.</i> , 30:1081 (1998)
	ACC	Kulkarni et al., "Programmed Cell Death Signaling Via Cell-Surface Expression of a Single-Chain Antibody Transgene," <i>Transplantation</i> , 69:1209-1217 (2000)
	ADD	Matsuoka et al., "A Novel Type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody without Participation of Complement," <i>J. Exp. Med.</i> , 181:2007-2015 (1995)
	AEE	Ohtomo et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells," <i>Biochem. Biophys. Res. Commun.</i> , 258:583-591 (1999)
	AFF	Oka, "Development of Novel Immunotoxin Using Recombinant Alpha-Sarcin and Its Application Treatment of Hematopoietic Tumor," <i>Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu</i> , 12:46-56 (1998) (concise English explanation included)
	AGG	Ono et al., "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cyto-toxicity," <i>Mol. Immunol.</i> , 36:387-395 (1999)
	AHH	Ozaki et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells," <i>Blood</i> , 93:3922-3930 (1999)
	AII	Ozaki et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24," <i>Blood</i> , 90:3179-3186 (1997)
	AJJ	Pettersen et al., "The TCR-Binding Region of the HLA Class I $\alpha$ 2 Domain Signals Rapid Fas-Independent Cell Death: A Direct Pathway for T Cell-Mediated Killing of Target Cells?" <i>J. Immunol.</i> , 160:4343-4352 (1998)
	AKK	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)
	ALL	Woodle et al., "Anti-Human Class I $\alpha$ 3 Domain-Specific Monoclonal Antibody Induces Programmed Cell Death in Murine Cells Expressing Human Class I MHC Transgenes," <i>Transplant. Proc.</i> , 30:1059-1060 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-141US1</b>	Application No. <b>10/530,696</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Shuji Ozaki et al.</b>	
		Filing Date <b>April 8, 2005</b>	Group Art Unit <b>1614</b>

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	AMM	Woodle et al., "Anti-Human Class I MHC Antibodies Induce Apoptosis by a Pathway That Is Distinct from the Fas Antigen-Mediated Pathway," <i>J. Immunol.</i> , 158:2156-2164 (1997)
	ANN	Woodle et al., "Class I MHC Mediates Programmed Cell Death in Human Lymphoid Cells," <i>Transplantation</i> , 64:140-146 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	